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Background: Receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) is a chondroitin sulphate (CS) transmembrane
protein tyrosine phosphatase and is a receptor for pleiotrophin (PTN). RPTPβ/ζ interacts with ανβ3 on the cell surface and
upon binding of PTN leads to c-Src dephosphorylation at Tyr530, β3 Tyr773 phosphorylation, cell surface nucleolin
(NCL) localization and stimulation of cell migration. c-Src-mediated β3 Tyr773 phosphorylation is also observed
after vascular endothelial growth factor 165 (VEGF165) stimulation of endothelial cells and is essential for VEGF
receptor type 2 (VEGFR2) - ανβ3 integrin association and subsequent signaling. In the present work, we studied
whether RPTPβ/ζ mediates angiogenic actions of VEGF.
Methods: Human umbilical vein endothelial, human glioma U87MG and stably transfected Chinese hamster
ovary cells expressing different β3 subunits were used. Protein-protein interactions were studied by a combination
of immunoprecipitation/Western blot, immunofluorescence and proximity ligation assays, properly quantified as
needed. RPTPβ/ζ expression was down-regulated using small interference RNA technology. Migration assays were
performed in 24-well microchemotaxis chambers, using uncoated polycarbonate membranes with 8 μm pores.
Results: RPTPβ/ζ mediates VEGF165-induced c-Src-dependent β3 Tyr773 phosphorylation, which is required for
VEGFR2-ανβ3 interaction and the downstream activation of phosphatidylinositol 3-kinase (PI3K) and cell surface NCL
localization. RPTPβ/ζ directly interacts with VEGF165, and this interaction is not affected by bevacizumab, while it
is interrupted by both CS-E and PTN. Down-regulation of RPTPβ/ζ by siRNA or administration of exogenous CS-E
abolishes VEGF165-induced endothelial cell migration, while PTN inhibits the migratory effect of VEGF165 to the
levels of its own effect.
Conclusions: These data identify RPTPβ/ζ as a cell membrane binding partner for VEGF that regulates angiogenic
functions of endothelial cells and suggest that it warrants further validation as a potential target for development
of additive or alternative anti-VEGF therapies.
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Vascular endothelial growth factor A (VEGF) is a growth
factor that activates several functions of endothelial cells,
thus triggering angiogenesis and vascular permeability. It
exists as different isoforms of 121, 145, 165, 189 and 206
amino acids, among which VEGF165 is dominant in terms
of amount and biological activity. VEGF165 is over-
expressed in a variety of human tumors, and its over-
expression is correlated with progression, invasion, and
metastasis of tumors. VEGF165 cell signaling leading to in-
creased endothelial cell migration and tubular formation
is mediated via vascular endothelial growth factor receptor
2 (VEGFR2), which interacts with co-receptors, such as
ανβ3 integrin [1]. It has been shown that c-Src-
mediated phosphorylation of β3 cytoplasmic tail tyro-
sine residues occurs in response to VEGF165 and is essen-
tial for VEGFR2-β3 integrin association and subsequent
signaling [2,3]. Up to date, it remains unclear how c-Src is
activated by VEGF165. The first step in c-Src activation
requires dephosphorylation of its carboxy-terminus
Tyr530 [4], suggesting that a tyrosine phosphatase may
be involved.
Receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ)
is a member of the family of receptor-type transmembrane
protein tyrosine phosphatases that interacts with several
cell adhesion molecules, such as neutral cell adhesion
molecule, neuron-glia cell adhesion molecule, tenascin
and contactin. It also acts as a receptor for the soluble,
heparin-binding growth factors midkine and pleiotro-
phin (PTN) [5]. RPTPβ/ζ and PTN are expressed in
endothelial cells [6] and over-expressed in several types
of cancer [5,7]. PTN binding to RPTPβ/ζ on endothelial
cells leads to Tyr530 dephosphorylation and activation
of c-Src, β3 Tyr773 phosphorylation, and PTN-induced
endothelial cell migration and tube formation on matri-
gel [5,8]. Besides PTN, RPTPβ/ζ has been shown to be
the putative receptor for the vacuolating cytotoxin
VacA produced by Helicobacter pylori [9], as well as a
functional receptor for interleukin-34 [10], suggesting
that it acts as a functional binding partner for several
soluble molecules.
We have recently shown that RPTPβ/ζ-induced, c-Src-
mediated β3 Tyr773 phosphorylation is also required for
PTN-induced cell surface nucleolin (NCL) localization
[11]. NCL is over-expressed on the plasma membrane of
cancer and activated endothelial cells and has been
shown to play critical roles in the modulation of tumori-
genesis and angiogenesis through its interaction with a
variety of ligands, among which tumor homing peptide
F3, endostatin, P-selectin and PTN [12]. VEGF165 in-
duces NCL localization on the surface of endothelial
cells and this effect is considered important for its angio-
genic actions [13,14]; however, the receptors and path-
ways involved have not been elucidated.In the present work, we explored the possibility that
RPTPβ/ζ is involved in the stimulatory effect of VEGF165
on endothelial cell signaling leading to cell migration.
Our data show that VEGF165 directly interacts with
RPTPβ/ζ to induce c-Src-mediated β3 Tyr773 phos-
phorylation. The latter is required for both cell surface
NCL localization and increased interaction of ανβ3 with
VEGFR2, leading to VEGF165-induced endothelial cell
migration.
Results and discussion
Phosphorylation of β3 Tyr773 is required for VEGF165-
induced cell migration and cell surface NCL localization
It has been shown that phosphorylation of β3 cytoplas-
mic Tyr 773 and 785 in response to VEGF165 plays a role
in endothelial cell migration [2]. In order to determine
which of the two Tyr is responsible for VEGF165-induced
cell migration, we used CHO cells that express VEGFR2
(Figure 1A), RPTPβ/ζ and αν [8,11], but do not express
β3 and are mock-transfected or stably transfected to
over-express wild-type β3 or β3 in which Tyr773 and/or
Tyr785 are mutated to Phe [11]. VEGF165 induced migra-
tion of CHO cells over-expressing wild type β3 or
β3Y785F, but had no effect on CHO cells over-expressing
β3Y773F or β3Y773F/Y785F (Figure 1B), suggesting that
β3 Tyr773 is important for VEGF165-induced cell migra-
tion. In the same line and similarly to what we have re-
cently shown for PTN [11], VEGF165-induced cell surface
NCL localization was only observed in CHO cells over-
expressing wild type-β3 or β3Y785F, while in cells over-
expressing β3Y773F, NCL remained restricted in the
cell nucleus, suggesting that β3 Tyr773 but not Tyr785
phosphorylation is important for VEGF165-induced cell
surface NCL localization (Figure 1C). Since RPTPβ/ζ is
involved in PTN-induced β3 Tyr773 phosphorylation
and cell surface NCL localization [8,11], these data lead
to the hypothesis that RPTPβ/ζ may also be involved in
VEGF165-induced signaling that leads to endothelial cell
migration.
RPTPβ/ζ plays a role in VEGF165-induced endothelial cell
signaling that leads to cell surface NCL localization
Since RPTPβ/ζ is responsible for PTN-induced β3 Tyr773
phosphorylation through dephosphorylation and activa-
tion of c-Src in human umbilical vein endothelial cells
(HUVEC) [8], we examined whether RPTPβ/ζ also affects
VEGF165-induced c-Src activation and β3 Tyr773 phos-
phorylation. Down-regulation of RPTPβ/ζ expression by
two different siRNAs abolished VEGF165-induced dephos-
phorylation of c-Src at Tyr530 (Figure 2A), suggesting that
RPTPβ/ζ may be the missing link for c-Src activation upon
stimulation of endothelial cells with VEGF165. Indeed, the
increase in dephosphorylated c-Src Tyr530 was mirrored
by higher phosphorylation of c-Src at Tyr419 (Figure 2A),
BA
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Figure 1 Phosphorylation of β3 Tyr773 is required for VEGF165-induced cell migration and cell surface NCL localization. (A) Protein extracts
of CHO cells were analysed for expression of VEGFR2. HUVEC were used as a positive control and β-actin as a loading control. (B) Effect of
VEGF165 (10 ng/ml) on CHO cell migration. Data are from five independent experiments and are expressed as mean ± s.e.m. percentage change in
number of migrating cells compared with the corresponding non stimulated cells (set as default 100). (C) Immunofluorescence images stained for NCL
(green) and nucleus (blue) in serum starved CHO cells treated with VEGF165 (10 ng/ml) for 5 h at 37°C. Vector, cells transfected with the plasmid vector;
wtβ3, cells over-expressing wild-type β3; β3Y773F, cells over-expressing β3Y773F; β3Y785F, cells over-expressing β3Y785F; β3Y773F/Y785F, cells
over-expressing double mutant β3Y773F/Y785F.
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VEGFR2 tyrosine kinase activity by the selective inhibi-
tor SU1498 or inhibition of VEGF-VEGFR2 interaction
by bevacizumab, did not affect VEGF165-induced c-Src
Tyr530 dephosphorylation or c-Src Tyr419 phosphoryl-
ation (Additional file 1), suggesting that c-Src activation
may be independent of VEGFR2 in these assays. RPTPβ/ζ
directly interacts with c-Src [6], an observation that is in
line with a role for RPTPβ/ζ in c-Src activation. Down-
regulation of RPTPβ/ζ expression also abolished VEGF165-
induced β3 Tyr773 phosphorylation (Figure 2B), suggest-
ing that RPTPβ/ζ may be involved in VEGF165-induced
signaling related to cell surface NCL localization, as has
been previously described for PTN [11]. Indeed, down-
regulation of RPTPβ/ζ expression abolished VEGF165-in-
duced cell surface NCL localization (Figure 2C). Although
it has been known for several years that VEGF165 induces
cell surface NCL localization [13], which is required for
VEGF165-induced cell migration [14], the receptor/path-
way involved was unknown up to date. The observationthat VEGF165-induced cell surface NCL localization de-
pends on RPTPβ/ζ suggests a role for RPTPβ/ζ in the an-
giogenic effects of VEGF165.
To further investigate the involvement of RPTPβ/ζ in
VEGF actions, we studied the role of several signaling
molecules known to be activated by both VEGF165 and
RPTPβ/ζ on cell surface NCL localization. Inhibition of
c-Src and phosphatidylinositol 3-kinase (PI3K) abolished
VEGF165-induced cell surface NCL localization, while in-
hibition of ERK1/2 had no effect (Figure 2D). In order to
investigate whether PI3K lays up- or downstream of
ανβ3, the effect of PI3K inhibition on VEGF165-induced
β3 Tyr773 phosphorylation was studied. The c-Src in-
hibitor PP1 was used as a positive control, since c-Src is
known to lay upstream of β3 Tyr773 phosphorylation
[2,8,11]. The p38 inhibitor (SB203580 10 μΜ, BioSource
Europe, Nivelles, Belgium) was used as a negative control,
since it has been previously shown not to affect RPTPβ/ζ-
mediated β3 Tyr773 phosphorylation and PI3K activation





Figure 2 (See legend on next page.)
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Figure 2 RPTPβ/ζ is required for VEGF165-induced cell surface NCL localization. Serum starved HUVEC were treated with VEGF165 (10 ng/ml)
for 10 min. Cell lysates were analyzed by Western blot for non Tyr530 phosphorylated (npc-Src), Tyr419 phosphorylated (pc-Src) and total (tc-Src)
c-Src (A), as well as for phospho-β3Y773 (pβ3Y773) and total β3 (tβ3) integrin (B). Numbers in brackets denote the average-fold change of the
ratio npc-Src:tc-Src, pc-Src:tc-Src or pβ3Y773:tβ3 respectively, compared with the corresponding non stimulated, untransfected cells (set as default 1).
(C) Representative immunofluorescence images stained for NCL (green), RPTPβ/ζ (red) and nucleus (blue) from serum starved HUVEC treated with
VEGF165 (10 ng/ml) for 5 h at 37°C. (D) Representative immunofluorescence images stained for NCL (green) and nucleus (blue) from serum starved
VEGF165-stimulated HUVEC in the presence or absence of inhibitors for c-Src (PP1 10 μΜ), PI3K (wortmannin 100 nM) and ERK½ (U0126 20 nM). Scale
bars in C and D correspond to 10 μm. (E) Lysates from serum starved VEGF165-stimulated HUVEC in the presence or absence of PP1 and wortmannin,
were analyzed by Western blot for pβ3Y773 and tβ3 integrin. Numbers in brackets denote the average-fold change of the ratio pβ3Y773:tβ3 compared
with untreated cells (set as default 1). (F and G) Phosphorylation of PI3K in HUVEC and CHO cells respectively. Data are expressed as mean ± s.e.m
percentage change in PI3K compared with the untreated cells (set as default 100). In all cases, data come from three independent experiments. siNeg,
HUVEC transfected with a negative control siRNA; siRPTPβ/ζ1, HUVEC transfected with siRPTPβ/ζ#1; siRPTPβ/ζ2, HUVEC transfected with si RPTPβ/ζ#2;
vector, CHO cells transfected with the plasmid vector; wtβ3, CHO cells over-expressing wild-type β3; β3Y773F, CHO cells over-expressing β3Y773F;
β3Y785F, CHO cells over-expressing β3Y785F.
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downstream of ανβ3. By using an ELISA for activated PI3K
in HUVEC, it was found that inhibition of c-Src abolished
VEGF165-induced PI3K activation (Figure 2F). Using the
same assay in CHO cells over-expressing wild-type β3,
β3Y773F or β3Y785F, it was found that VEGF165 signifi-
cantly induced PI3K activation in CHO cells over-
expressing wild-type β3 or β3Y785F, while it had no effect
in cells over-expressing β3Y773F (Figure 2G), suggesting
that PI3K lays downstream of ανβ3 and requires β3 Tyr773
phosphorylation. This pathway resembles the one we have
recently shown for PTN-induced cell surface NCL
localization [11], further supporting the notion that
RPTPβ/ζ mediates this effect of VEGF165. Similarly to
what has been previously discussed for PTN, it remains
unclear how PI3K affects cell surface NCL localization.
Co-immunoprecipitation of NCL with PI3K [15,16]
favors a direct regulation of NCL by PI3K and one
possibility is by regulating the trafficking of exocytotic
vesicles. NCL has been detected in cytoplasmic vesicles
fused with the plasma membrane [17], while inhibition
of PI3K interferes with the trafficking of such exocytotic
vesicles, affecting the number of several receptors on
the plasma membrane, such as the transferrin receptor
[18], the glucose transporter GLUT4 [19] or β integrin
[20]. Alternatively, PI3K may indirectly regulate cell
surface NCL localization, by regulating recruitment
of proteins containing pleckstrin homology domains
onto the cell membrane [21]. NCL does not possess
such sequences but may act as a ligand for proteins
containing pleckstrin homology domains through its
acidic motifs [22].
RPTPβ/ζ plays a role in VEGF165-induced interaction of
VEGFR2 with ανβ3
Based on the literature that c-Src–mediated phosphorylation
of β3 essentially regulates VEGF165-induced interaction
of ανβ3 with VEGFR2 in endothelial cells [2] and our
observation that RPTPβ/ζ is required for VEGF165-induced c-Src activation and β3 Tyr773 phosphorylation
(Figure 2), we tested the hypothesis that RPTPβ/ζ may
have a role in the interaction of ανβ3 with VEGFR2.
Down-regulation of RPTPβ/ζ expression by siRNA
abolished the increased interaction of ανβ3 with VEGFR2
induced by VEGF165, as evidenced by both immunopre-
cipitation/Western blot (Figure 3A) and proximity
ligation assays (PLA) (Figure 3B). These data also show
involvement of RPTPβ/ζ in VEGF-induced endothelial
cell migration.
RPTPβ/ζ plays a role in VEGF165-induced endothelial cell
migration
Since RPTPβ/ζ affects VEGF165-induced signaling related to
cell migration, we tested whether it also affects VEGF165-
induced endothelial cell migration. Down-regulation of
RPTPβ/ζ expression by siRNA abolished VEGF165-
induced HUVEC migration (Figure 4), highlighting a role
for RPTPβ/ζ in the angiogenic effects of VEGF165.
VEGF directly interacts with RPTPβ/ζ
It has been previously shown that RPTPβ/ζ interacts
with both ανβ3 and NCL in HUVEC [8,11], both of
which are involved in VEGF165-induced endothelial cell
migration [2,3,13,14]. Since VEGFR2 is also required for
VEGF165-induced endothelial cell migration [1], we
tested whether RPTPβ/ζ interacts with VEGFR2. By
performing immunoprecipitation/Western blot and PLA
assays, we found that VEGFR2 does not associate with
RPTPβ/ζ (Figure 5A). We then tested the possibility that
VEGF directly associates with RPTPβ/ζ by performing
PLA assays in HUVEC, which express endogenous levels
of VEGF (Additional file 2). As shown in Figure 5B,
endogenous VEGF formed complexes with RPTPβ/ζ,
suggesting a direct interaction between the two
molecules. Interestingly, addition of exogenous VEGF165
to HUVEC, which led to increased VEGF immunostaining
(Additional file 2), increased VEGF-RPTPβ/ζ PLA signals
(Figure 5B), verifying the specificity of the signal. In these
AB
Figure 3 RPTPβ/ζ regulates VEGF165-induced VEGFR2-ανβ3 interaction. Down-regulation of RPTPβ/ζ expression by siRNA was followed by treatment
of serum-starved HUVEC with VEGF165 (10 ng/ml) for 10 min. (A) Cells lysates were immunoprecipitated for β3 and analyzed by Western blot
for the presence of VEGFR2 and β3. (B) Formation of β3-VEGFR2 complexes as evidenced by in situ PLA. The box plots indicate the median,
mean and range of the detected signals (n = 8 image fields with ~4 cells per image per sample type, each sample run in duplicate). Scale bar
corresponds to 10 μm. siNeg, HUVEC transfected with a negative control siRNA; siRPTPβ/ζ, HUVEC transfected with siRPTPβ/ζ#1.
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positive control. Interaction of VEGF with RPTPβ/ζ was
also observed in human glioblastoma U87MG cells, by
using a combination of immunoprecipitation/Westernblot, double immunofluorescence and PLA assays.
These cells express higher levels of endogenous VEGF
compared with HUVEC and the PLA signals showing
interaction with RPTPβ/ζ were also higher than those
Figure 4 RPTPβ/ζ is required for VEGF165-induced endothelial cell migration. Effect of VEGF165 on HUVEC migration after down-regulation
of RPTPβ/ζ expression by two different siRNAs. Data are from five independent experiments and are expressed as mean ± s.e.m. percentage
change in number of migrating cells compared with the non stimulated untransfected cells (set as default 100). Untrasfected, untransfected
HUVEC; siNeg, HUVEC transfected with a negative control siRNA; siRPTPβ/ζ1, HUVEC transfected with siRPTPβ/ζ#1; siRPTPβ/ζ2, HUVEC transfected
with si RPTPβ/ζ#2. The Western blot on top shows effective down-regulation of RPTPβ/ζ by both siRNA sequences used.
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VEGF was not found to interact with ανβ3 (Additional
file 3).
Bevacizumab used at a concentration that inhibits
VEGF-induced cell migration and binding to both
VEGFR1 and VEGFR2 [23], did not affect interaction of
VEGF with RPTPβ/ζ (Figure 5C), suggesting that this
interaction involves a different region on the VEGF
molecule than the VEGFR binding site. Supporting this
notion, bevacizumab did not inhibit VEGF165-induced cell
surface NCL localization (Figure 5D), which is also medi-
ated by RPTPβ/ζ as discussed above. Bevacizumab at the
same concentration significantly inhibited interaction of
VEGF with VEGFR2 (Additional file 4). These data clearly
indicate that although binding to VEGFR2 is essential for
VEGF-induced endothelial cell migration [2], some of the
angiogenic actions of VEGF, such as cell surface NCL
localization, are not inhibited by bevacizumab. Taking into
account that angiogenic factors, such as PTN, hepatocytegrowth factor and even VEGF itself act through cell surface
NCL [12], the lack of effect of bevacizumab on VEGF165-
induced cell surface NCL localization may explain at least
some of the cases of resistance development to bevacizu-
mab, e.g. in glioblastomas, where classical VEGF signaling
through VEGFRs has been found to remain inhibited [24].
Moreover, our data provide a mechanistic support to the
notion that RPTPβ/ζ is a valuable target for glioblastoma
therapies [25,26].
There are two transmembrane isoforms of RPTPβ/ζ,
the long isoform that has been described as a CS proteo-
glycan, and the short isoform considered a glycoprotein.
Up to date, it is still unclear which of the two RPTPβ/ζ
isoforms are responsible for each of its actions and it is
not known whether glycosylation of these isoforms dif-
fers among different types of cells. Efforts to identify its
CS glycanation suggest that it is regulated both develop-
mentally and in different pathophysiological situations
[27] and our unpublished observations based on Western
BA
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Figure 5 (See legend on next page.)
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Figure 5 VEGF directly interacts with RPTPβ/ζ in a VEGFR-independent manner. (A) Serum-starved untreated or VEGF165-stimulated HUVEC lysates
were immunoprecipitated for VEGFR2 and analyzed by Western blot for the presence of RPTPβ/ζ or VEGFR2 (up). No direct interaction between VEGFR2
with RPTPβ/ζ was observed by performing in situ PLA in HUVEC (down). The RPTPβ/ζ-ανβ3 interaction was used as a positive control. Data are from two
independent experiments. (B) Formation of VEGF-RPTPβ/ζ complexes as evidenced by in situ PLA in HUVEC, untreated or after addition of exogenous
VEGF165 (10 ng/ml) at 24 h. The VEGF-VEGFR2 interaction was used as a positive control. Data are from five independent experiments. (C) Formation of
VEGF-RPTPβ/ζ complexes as evidenced by in situ PLA in HUVEC in the absence or the presence of bevacizumab (250 μg/ml). The box plots in
B and C indicate the median, mean and range of the detected signals (n > 20 image fields with ~4 cells per image per sample type, each sample run
at least in duplicate) from three independent experiments. (D) Immunofluorescence images stained for NCL (green) and nucleus (blue) in serum
starved HUVEC treated for 5 h at 37°C with VEGF165 (10 ng/ml) in the presence or the absence of bevacizumab (250 μg/ml). Representative pictures
from three independent experiments. Scale bars in all cases correspond to 10 μm.
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types support the notion of a cell-type specific RPTPβ/ζ
glycosylation. PTN binding to RPTPβ/ζ involves both low
(Kd = 3 nM) and high (Kd = 0.25 nM) affinity binding sites
[28], which represent more than one sites of interaction
that involve both the protein core and the CS chains of
the receptor [5]. Oversulfation of CS is essential for PTN
affinity and PTN-mediated functions [29-32], which is in
line with our observation that CS-E inhibits interaction of
PTN with RPTPβ/ζ in both HUVEC and U87MG cells
(Additional file 5). It should be noted, however, that
although inhibition in U87MG cells was at the level of
70% (total signals per cell in control: 23 ± 7 and in CS-E
treated cells: 8 ± 1), in HUVEC it was smaller, at the level
of 50% (total signals per cell in control: 6 ± 0.4 and in
CS-E treated cells: 3 ± 0.3).
Since VEGF has been shown to be able to bind to CS-
E similarly to heparan sulphate, but does not bind CS-C
or CS-A [33], we investigated whether CS-Ε also inhibits
VEGF interaction with RPTPβ/ζ. CS-E decreased inter-
action of VEGF with RPTPβ/ζ in U87MG cells (Additional
file 6), but had no effect on HUVEC (Figure 6A), in line
with the observation that it did not affect VEGF165-induced
cell surface NCL localization (Figure 6B). This difference
could be explained by the hypothesis that cell surface NCL
localization depends on the interaction of VEGF with the
short, non-proteoglycan isoform of RPTPβ/ζ. Interestingly
and in favor of such a possibility, in U87MG cells that ex-
press higher amounts of endogenous VEGF than HUVEC,
we performed IP/Western blot assays and observed that
CS-E inhibits interaction of both PTN and VEGF with the
long, but not the short RPTPβ/ζ isoform (Additional file 6).
These data suggest that interaction of VEGF (and PTN)
with the short RPTPβ/ζ isoform may not involve CS-E
chains. On the other hand, CS-E abolished VEGF165-
induced HUVEC migration (Figure 6C), an effect that
may involve a different cell surface molecule or parallel
signaling pathways that are important for cell migration.
This point is under further investigation.
The idea that the interaction of VEGF with RPTPβ/ζ
does not involve its heparin-binding properties isfurther supported by the observation that VEGF121,
which induces HUVEC migration but does not contain
the heparin-binding site of VEGF [34], also induces cell
surface NCL localization (Figure 6D). Collectively, our
data suggest that interaction of VEGF with RPTPβ/ζ may
involve a part of the molecule that is distinct from those
involved in VEGFR or glycosaminoglycan binding. This
notion is similar to the recent finding that the high affinity
neuropilin-1 binding of VEGF-A involves the exon
8-encoded C-terminal Arg [35]. Tuftsin, a naturally
occurring TKPR peptide with sequence similarity to the
sequence coded by exon 8 of VEGF, blocks VEGF165-
induced autophosphorylation of VEGFR2, without inhi-
biting VEGF binding to VEGFR2 [36]. Taking into account
that PTN binding to RPTPβ/ζ involves PTN's carboxy
terminal region that is rich in basic amino acids [37], and
that PTN inhibits VEGF binding to RPTPβ/ζ (see below),
one can speculate that binding of VEGF to RPTPβ/ζ might
be mediated by its exon 8-encoded sequence.
Finally, we found that the interaction of VEGF with
RPTPβ/ζ was decreased in the presence of PTN in
both HUVEC (Figure 7A) and U87MG cells (Additional
file 7), suggesting that these two growth factors share a
common binding site on RPTPβ/ζ. This is further sup-
ported by the observation that the PTN-RPTPβ/ζ inter-
action was also decreased in the presence of exogenous
VEGF165 (Figure 7B). It has been previously suggested
that besides the CS chains, the core RPTPβ/ζ protein is
also involved in binding to PTN [28,38], which may also
be the site of interaction of the short RPTPβ/ζ trans-
membrane isoform with VEGF, as discussed above.
PTN stimulates human endothelial cell migration by
approximately 40% [6,8,11], an effect that is smaller
than that of other growth factors, such as VEGF. Inter-
estingly, PTN decreased VEGF165-induced HUVEC mi-
gration to the levels of its own, smaller stimulatory effect
(Figure 7C), in agreement with a previous study showing
that PTN did not abolish but decreased VEGF165-induced
endothelial cell infiltration of matrigel in vivo to the levels
of its own stimulation [39]. These data favor the notion




Figure 6 Effect of CS-E on VEGF165-induced endothelial cell signaling and migration. (A) Formation of VEGF-RPTPβ/ζ complexes as evidenced by in
situ PLA in HUVEC in the absence or the presence of CS-E II (100 ng/ml). The box plots indicate the median, mean and range of the detected
signals (n > 20 image fields with ~4 cells per image per sample type, each sample run at least in duplicate) from three independent experiments.
(B) Immunofluorescence images stained for NCL (green) and nucleus (blue) in serum starved HUVEC treated for 5 h at 37°C with VEGF165 (10 ng/ml) in
the absence or the presence of CS-E II (100 ng/ml). Representative pictures from two independent experiments. (C) Effect of CS-E I and II (both at
100 ng/ml) on VEGF165-induced HUVEC migration. Data are from three independent experiments and are expressed as mean ± s.e.m. percentage
change in number of migrating cells compared with the non stimulated untransfected cells (set as default 100). (D) Immunofluorescence images
stained for NCL (green) and nucleus (blue) in serum starved HUVEC treated for 5 h at 37°C with VEGF121 (10 ng/ml). Representative pictures from two
independent experiments. Scale bars in all cases correspond to 10 μm.
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a regulator of angiogenesis, by limiting the aberrant effect
of VEGF, while it still induces a smaller, significant stimu-
latory effect.
It is important to note that although RPTPβ/ζ is required
for cell migration induced by PTN [6] and VEGF165(present study), it is not sufficient by itself to induce cell
migration, based on our previous data showing that mid-
kine [8] or PTN112–136 [40], which lead to c-Src Tyr530 de-
phosphorylation and β3 Τyr773 phosphorylation through
RPTPβ/ζ, do not induce endothelial cell migration. It
seems that other receptors/signaling pathways are activated
BA
C
Figure 7 PTN and VEGF compete for binding to RPTPβ/ζ. (A) Formation of VEGF-RPTPβ/ζ complexes as evidenced by in situ PLA in HUVEC in
the absence or the presence of exogenous PTN (100 ng/ml). (Β) Formation of PTN-RPTPβ/ζ complexes as evidenced by in situ PLA in HUVEC in
the absence or the presence of exogenous VEGF165 (10 ng/ml). The box plots in A and B indicate the median, mean and range of the detected
signals (n > 20 image fields with ~4 cells per image per sample type, each sample run at least in duplicate) from three independent experiments
in each case. (C) Effect of PTN (100 ng/ml) on VEGF165-induced HUVEC migration. Data are from five independent experiments and are expressed
as mean ± s.e.m. percentage change in number of migrating cells compared with the non stimulated untransfected cells (control, set as default
100). Asterisks denote a statistically significant difference from control. ***P < 0.001.
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plementarily induce cell migration. Such a pathway for
VEGF165 involves at least VEGFR2 and the cross-talk of sig-
naling molecules activated by VEGF165 through RPTPβ/ζ,
ανβ3 and VEGFR2 or other cell surface binding molecules
in different cell types is under further investigation.Conclusion
RPTPβ/ζ is a receptor-type protein tyrosine phosphatase
expressed in several types of cancer and involved in cell
migration, cancer progression and metastasis [5,27]. The
current study identifies RPTPβ/ζ as a novel cell mem-
brane binding molecule for VEGF165, which regulates c-
Src-mediated β3 Tyr773 phosphorylation and interaction
with VEGFR2, cell surface NCL localization through
PI3K activation and endothelial cell migration (Figure 8).
These data are of high significance, especially taking into
account that the interaction of VEGF with RPTPβ/ζ and
the downstream angiogenic VEGF actions, such as cell
surface NCL localization, do not seem to be affected by
existing anti-VEGF drugs, such as bevacizumab, and may
explain the resistance developed by tumor types, e.g.
glioblastoma, in such therapies [24,41]. They thus warrant
exploitation of RPTPβ/ζ for the possible development of
alternative or additive anti-angiogenic therapies, especially
in cases where resistance develops.Figure 8 Schematic representation of the proposed mechanism that in
surface NCL localization and stimulation of cell migration by VEGF. Bind
leads to c-Src activation, β3 Tyr773 phosphorylation and increased interaction
from the nucleus to the cell membrane. Both are required for VEGF165-induceMethods
Materials
Human recombinant VEGF165 was prepared as previously
described [39]. VEGF121 was purchased from RELIATech
GmbH (Wolfenbüttel, Germany). Bevacizumab (AVAS-
TIN) was from Roche Applied Science (Indianapolis, IN,
USA). Human recombinant PTN was from PeproTech,
Inc. (Rocky Hill, NJ, USA) or prepared as previously de-
scribed [39]. PTN from both sources was equally active
in all cases. CS-E was either from Seikagaku Corpor-
ation (Tokyo, Japan) (CS-E I), or prepared from a crude
preparation of squid cartilage CS (purchased from
Yantai Changsen Chemical Co., Ltd., Shandong, China)
(CS-E II), both sources being equally active. PP1, wort-
mannin and U0126 were from TOCRIS (Minneapolis,
MN, USA) and SU1498 was from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA). All secondary
horseradish peroxidase-conjugated antibodies were
from Cell Signaling Technology Inc. (Beverly, MA,
USA). Human IgG and other reagents were from Sigma
(St. Louis, MO, USA).
Cell culture
HUVEC, human glioma U87MG cells and CHO cells ex-
pressing αν but deficient in endogenous β3 integrin or sta-
bly transfected to express wild type β3, β3Y773F, β3Y785F
or β3Y773F/Y785F were cultured as previously describedvolves RPTPβ/ζ and leads to increased ανβ3-VEGFR2 interaction, cell
ing of VEGF165 to RPTPβ/ζ on the surface of endothelial or cancer cells
of ανβ3 with VEGFR2, as well as PI3K activation and translocation of NCL
d endothelial cell migration. For more details see text.
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(Seromed, Germany). All cultures were maintained at
37°C, 5% CO2, and 100% humidity. When cells reached
70-80% confluence, they were serum starved for 16 h
(where indicated) before performing migration assays,
lysed for immunoprecipitation/Western blot assays or
fixed for immunofluorescence assays and in situ PLA.Immunofluorescence
Cells were fixed with 4% formaldehyde in phosphate-
buffered saline (PBS) pH 7.4 for 10 min and perme-
abilized with 0.1% Triton in PBS for 15 min. After being
washed 3 times with PBS, the cells were blocked with
PBS containing 3% BSA and 10% fetal bovine serum
(FBS) for 1 h at room temperature. Cells were stained
with the following primary antibodies: rabbit anti-VEGF
(1:250; Santa Cruz Biotechnology Inc.), mouse anti-
RPTPβ/ζ (1:250; BD Biosciences, San Diego, CA, USA),
mouse anti-ανβ3 (1:500; Merck Millipore, Darmstadt,
Germany), and rabbit anti-NCL (1:1,000, Sigma). Cells were
then incubated with fluorescent Alexa secondary antibodies
(1:500; Molecular Probes, Carlsbad, CA, USA). Nuclei were
stained with Draq5 (Biostatus Limited, Leicestershire,
UK). Cells were mounted with Mowiol 4–88 (Merck
Millipore) and visualized at room temperature with
Leica SP5 (X63 objective with a numerical aperture of
1.4) confocal microscope.In situ PLA
For detection of protein-protein interactions, in situ PLA
was performed. The components used (Sigma) were as
follows: anti-mouse PLA plus probe, anti-rabbit PLA
minus probe and Detection Reagents Orange. HUVEC or
U87MG cells were grown on μ-Chamber 12 well on glass
slides (Ibidi©, Martinsried, Germany). After reaching 80%
confluence or after appropriate treatment of cells, the
assay was performed according to the manufacturer’s in-
structions. Briefly, after fixation and blocking, cells were
incubated with the primary antibodies: mouse anti-
VEGF (1:250), rabbit anti-VEGF (1:250), rabbit anti-Flk-1
(1:250), mouse anti-Flk-1 (1:250), mouse anti-NCL (1:50),
goat anti-RPTPβ/ζ (1:250) (all from Santa Cruz Biotech-
nology Inc.), mouse anti-ανβ3 (1:500; Merck Millipore),
mouse anti-PTN (1:500; Abnova, Heidelberg, Germany)
and mouse anti-RPTPβ/ζ (1:250; BD Biosciences). Subse-
quently, cells were incubated with secondary antibodies
conjugated with oligonucleotides. After hybridization and
ligation of the oligonucleotides, the DNA was amplified. A
detection mixture detected the amplicons, resulting in
red fluorescence signals. Nuclei were counterstained
with Draq5; cells were mounted with Mowiol 4–88 and
visualized at room temperature with Leica SP5 confocal
microscope.Quantification of in situ PLA signals
Estimation of nuclei and cytoplasm size was performed
using the Duolink ImageTool software (Olink Bioscience).
In order to calculate the total number of spots per cell,
an algorithmic procedure was developed and imple-
mented in the Matlab environment (The MathWorks Inc.,
Massachusetts, USA). “I” denotes an immunofluorescence
image of m × n size. Such an image can be seen as a
“stack” of three matrices of the same size; representing
the red, green and blue values for each pixel indicated
as IR, IG, IB for the three color bands, respectively. For
every pixel at position (i, j) correspond three values;
IR(i, j), IG(i, j), IB(i, j), ranging from 0 to 255. Image
pre-processing was performed to identify pixels of red
intensities less than a determined threshold value θ, in
order to exclude background noise. Several values were
tested and evaluated and finally θ was set to 50. In
order to detect a red dot, the algorithm searches the
red band (i.e., the IR matrix) for a group of at least c
connected pixels. The value of the parameter c, which
controls the minimum number of pixels that constitute
a dot, c was set to 10. Moreover, in the case of overlapping
dots, large groups of pixels were identified. In such cases,
the true number of dots was calculated as [n /100] since a
typical dot contains approximately 100 pixels, where n is
the total number of pixels of the initial group and the op-
erator [α] is used to round the number α into its nearest
integer.
RNA interference
Cells were grown to 50% confluence in medium without
antibiotics. Transfection was performed in serum-free
medium for 4 h using annealed RNA for RPTPβ/ζ
(siRPTPβ/ζ#1, VBC Biotech Services, Vienna, Austria), as
previously described [6]. Another siRNA sequence for
RPTPβ/ζ (siRPTPβ/ζ#2, Hs_PTPRZ1_1 FlexiTube siRNA,
Qiagen GmbH, Germany) was also used as a control
for off-target effects. JetSI-ENDO (Polyplus Transfec-
tion, Illkirch, France) or Lipofectamine® RNAiMAX
(Life Technologies) were used as transfection reagents.
Double-stranded negative control siRNA (Ambion,
Austin, TX, USA) was used in all experiments. Cells
were incubated for another 48 h in serum-containing
medium and lysed, serum starved or fixed before fur-
ther experiments.
Migration assays
Migration assays were performed as previously de-
scribed [8,11] in 24-well microchemotaxis chambers
(Corning, Inc., Lowell, MA, USA) using uncoated poly-
carbonate membranes with 8 μm pores. Serum-starved
cells were harvested, resuspended at a concentration of
105 cells/0.1 ml in serum-free medium containing
0.25% bovine serum albumin (BSA) and loaded in the
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0.6 ml of serum-free medium containing 0.25% BSA
and the tested substances. Cells were incubated for 4 h
at 37°C. After completion of the incubation, filters were
fixed and stained with 0.33% toluidine blue solution.
The cells that migrated through the filters were quanti-
fied by counting the entire area of each filter, using a
grid and a microscope with a X20 objective (Optech
Microscope Services Ltd., Thames, UK).
PI3K p85 ELISA
The levels of total and phosphorylated PI3K p85 were
quantified using Fast Activated Cell-based ELISA assays
(Active Motif, Carlsbad, CA, USA) according to the
manufacturer's instructions. Briefly, cells were cultured
in 96-well plates one day prior to manipulation. Serum
starved CHO cells or HUVEC were treated with 10 ng/
ml VEGF165 for 10 min (in the presence or absence of
inhibitors of signaling molecules where appropriate),
fixed and incubated with anti–phospho and anti-total
p85 antibodies.
Immunoprecipitation assay
Cells were lysed with RIPA buffer, as previously described
[8]. Three mg of total protein were incubated with primary
antibody for 16 h at 4°C under continuous agitation. The
primary antibodies used were: mouse anti-VEGF (3 μg),
mouse anti-Flk-1 (3 μg), goat anti-RPTPβ/ζ (3 μg), goat
anti-PTN (3 μg) (Santa Cruz Biotechnology Inc.) and goat
anti-β3 (1.5 μg; Merck Millipore). Protein A- and protein
G-agarose beads (Merck Millipore) were added, samples
were further incubated for 2 h at 4°C, and beads with
bound proteins were collected by centrifugation (5,000 g
for 5 min at 4°C) and washed twice with ice-cold PBS
pH 7.4. Immunoprecipitated proteins were resuspended in
SDS loading buffer and analyzed by Western blot.
Western blot analysis
Proteins were analyzed by SDS-PAGE and transferred to
Immobilon P membranes. Blocking was performed by in-
cubating the membranes with Tris-buffered saline (TBS)
pH 7.4 with 0.05% Tween (TBS-T), containing either 5%
nonfat dry milk or 3% BSA. Membranes were incubated
with primary antibodies for 16 h at 4°C under continuous
agitation, washed 3 times with TBS-T, and incubated with
secondary antibodies for 1 h at room temperature. Pri-
mary antibodies used were mouse anti-Flk-1 (1:500), goat
anti-β3 (1:500), mouse anti-VEGF (1:500), rabbit anti-
phospho-β3(Y773) (1:1,000; Santa Cruz Biotechnology
Inc.), mouse anti-RPTPβ/ζ (1:500; BD Biosciences), rabbit
anti-c-Src (1:1,000; Merck Millipore), rabbit anti-phospho-
c-Src(Y418) (1:1,000; Acris Antibodies GmbH) and rabbit
anti-non-phospho-c-Src (1:1,000; Cell Signaling Tech-
nology Inc.). Detection of immunoreactive bands wasperformed using the enhanced chemiluminescence detec-
tion kit (Pierce Biotechnology, Rockford, IL, USA). Protein
levels were quantified using the ImagePC image analysis
software (Scion Corp., Frederick, MD, USA).
Statistical analysis
Results are expressed as mean ± s.e.m. or by using box
plots, where the box is determined by the 25th and 75th
percentiles, the whiskers are determined by the 5th and
95th percentiles, the line in the box marks the median
and the empty square in the box marks the mean. Out-
liers have been plotted as individual points. Where
applicable, variability between the results from each
group and the corresponding control was determined by
unpaired t test.
Additional files
Additional file 1: c-Src activation may be independent of VEGF-
VEGFR2 interaction. Serum starved HUVEC were treated with VEGF165 (10
ng/ml) for 10 min in the presence or absence of either the selective VEGFR2
tyrosine kinase inhibitor SU1498 (10 μΜ) or bevacizumab (250 μg/ml). Cell
lysates were analyzed by Western blot for non Tyr530 phosphorylated
(npc-Src), Tyr419 phosphorylated (pc-Src) and total (tc-Src) c-Src. Numbers in
brackets denote the average-fold change of the ratio npc-Src:tc-Src or
pc-Src:tc-Src respectively, compared with the corresponding non stimulated,
untransfected cells (set as default 1) from three independent experiments.
Additional file 2: VEGF-RPTPβ/ζ interaction in human glioma U87MG
cells. (A) Immunofluorescence images of HUVEC and U87MG cells stained
for VEGF (green) and nucleus (blue). Representative pictures from three
and two independent experiments respectively. (B) U87MG cell lysates
were immunoprecipitated for RPTPβ/ζ or VEGF. Immunoprecipitates
were analyzed by Western blot for the presence of VEGF or RPTPβ/ζ,
respectively. IgG was used as a negative control. Representative blots
from two independent experiments. (C) Immunofluorescence images of
U87MG cells stained for VEGF (green), RPTPβ/ζ (red) and nucleus (blue).
Representative pictures from two independent experiments. (D) In situ
PLA signals were detected as red dots, indicating the direct formation
of VEGF- RPTPβ/ζ complexes. Representative pictures from three independent
experiments. Scale bars in A, C and D correspond to 10 μm. (E) Formation of
VEGF-RPTPβ/ζ complexes as evidenced by in situ PLA in HUVEC and U87MG
cells. The box plots indicate the median, mean and range of the detected
signals (n > 20 image fields with 4-6 cells per image per sample type, each
sample run in duplicate) from four independent experiments.
Additional file 3: VEGF does not interact with ανβ3. (A)
Immunofluorescence images of U87MG cells cultured in serum-containing
medium and stained for VEGF (green), ανβ3 (red) and nucleus (blue).
Representative pictures from two independent experiments. (B) The
absence of in situ PLA signals indicates lack of the VEGF-ανβ3 direct
interaction in both HUVEC and U87MG cells. The PTN-ανβ3 interaction
in both types of cells was used as a positive control. Representative
pictures from two independent experiments.
Additional file 4: Bevacizumab inhibits VEGF-VEGFR2 interaction.
Formation of VEGF-VEGFR2 complexes as evidenced by in situ PLA in
HUVEC in the absence or the presence of bevacizumab (250 μg/ml). The
box plots indicate the median, mean and range of the detected signals
(n > 20 image fields with ~4 cells per image per sample type, each
sample run at least in duplicate) from two independent experiments.
Scale bars in all cases correspond to 10 μm.
Additional file 5: CS-E inhibits PTN-RPTPβ/ζ interaction in both HUVEC
and U87MG cells. Formation of PTN-RPTPβ/ζ complexes as evidenced by in
situ PLA in HUVEC (A) and U87MG cells (B) in the absence or presence of CS-E
II (100 ng/ml). The box plots indicate the median, mean and range of
Koutsioumpa et al. Molecular Cancer  (2015) 14:19 Page 15 of 16the detected signals (n = 20 image fields with ~6 cells per image per
sample type, each sample run in duplicate) from four (A) and three (B)
independent experiments. Scale bars in all cases correspond to 10 μm.
Additional file 6: CS-E inhibits VEGF-RPTPβ/ζ interaction in U87MG
cells. (A) Formation of VEGF-RPTPβ/ζ complexes as evidenced by in situ PLA
in U87MG cells in the absence or presence of CS-E II (100 ng/ml). The box
plots indicate the median, mean and range of the detected signals (n = 8
image fields with ~4 cells per image per sample type, each sample run in
duplicate) from three independent experiments. Scale bar corresponds
to 10 μm. (B) U87MG cell lysates were immunoprecipitated for VEGF.
Immunoprecipitates were analyzed by Western blot for the presence of
RPTPβ/ζ. (C) U87MG cell lysates were immunoprecipitated for PTN.
Immunoprecipitates were analyzed by Western blot for the presence of
RPTPβ/ζ. In B and C, representative blots from two independent
experiments are shown.
Additional file 7: PTN inhibits VEGF-RPTPβ/ζ interaction in U87MG
cells. (A) Formation of VEGF-RPTPβ/ζ complexes as evidenced by in situ PLA
in U87MG cells in the absence or presence of PTN (100 ng/ml). The box
plots indicate the median, mean and range of the detected signals (n = 6
image fields with ~ 5 cells per image per sample type, each sample run
in duplicate). Scale bar corresponds to 10 μm. Data come from three
independent experiments. (B) Cell lysates were immunoprecipitated for
RPTPβ/ζ. Immunoprecipitates were analyzed by Western blot for the
presence of VEGF. IgG was used as a negative control. Representative
blots from two independent experiments.
Abbreviations
BSA: Bovine serum albumin; CS: Chondroitin sulphate; ELISA: Enzyme-linked
immunoassay; FBS: Fetal bovine serum; NCL: Nucleolin; PBS: Phosphate
buffered saline; PI3K: Phosphatidylinositol 3-kinase; PLA: Proximity ligation
assay; PTN: Pleiotrophin; RPTPβ/ζ: Receptor protein tyrosine phosphatase
beta/zeta; TBS: Tris-buffered saline; VEGF: Vascular endothelial growth factor;
VEGFR2: Vascular endothelial growth factor receptor 2.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MK, EPo and EPap participated in research design. MK and EPa performed
PLA assays and EPa, AS and VM contributed analytical tools for PLA signal
quantification. MK, EPo, EPa and CT performed immunoprecipitation/Western
blot assays. SM and KS prepared CS-E and provided expertise on CS. NK
provided stably transfected cell lines and expertise on integrins. JC contributed
new analytic tools. MK, EPo, EPa, CT, AS and EPap performed data analysis.
All authors contributed to the writing of the manuscript. All authors read and
approved the manuscript.
Acknowledgements
This work was supported by the European Union (European Social Fund –
ESF, Heracleitus II (to M. Koutsioumpa - E. Papadimitriou), Thales (to V.
Megalooikonomou) and ΙΚΥ Fellowship of Excellence for Postgraduate
studies in Greece - Siemens Program (to E. Pantazaka). This work was also
supported in part by a Grant-in-Aid for Scientific Research for Challenging
Exploratory Research 25670018 (to K. Sugahara) from the Japan Society for the
Promotion of Science (JSPS). The authors thank the Advanced Light Microscopy
facility of the Medical School, University of Patras for using the Leica SP5 confocal
microscope and the PhD candidate Margarita Lamprou for technical support.
Author details
1Laboratory of Molecular Pharmacology, Department of Pharmacy, University
of Patras, GR 26504 Patras, Greece. 2Computer Engineering and Informatics
Department, University of Patras, GR 26504 Patras, Greece. 3Sino-French
Research Centre for Life Sciences and Genomics, CNRS/LIA124, Rui Jin
Hospital, Jiao Tong University Medical School, Shanghai, China. 4Laboratoire
CRRET, Universite Paris Est Creteil Val de Marne, Paris, France. 5Proteoglycan
Signaling and Therapeutics Research Group, Faculty of Advanced Life
Science, Hokkaido University, Sapporo, Japan. 6Current address: Center for
Systems Biomedicine, Division of Digestive Diseases, David Geffen School of
Medicine, University of California Los Angeles, Los Angeles, CA, USA. 7Currentaddress: Department of Pathobiochemistry, Faculty of Pharmacy, Meijo
University, Nagoya 463-8503, Japan.
Received: 22 May 2014 Accepted: 2 January 2015
References
1. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial
growth factor receptors. Cold Spring Harb Perspect Med. 2012;2:a006502.
2. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of
integrin-vascular endothelial growth factor receptor cross-activation in
angiogenesis. Circ Res. 2007;101:570–80.
3. Somanath PR, Malinin NL, Byzova TV. Cooperation between integrin
alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis. 2009;12:177–85.
4. Ingley E. Src family kinases: regulation of their activities, levels and
identification of new pathways. Biochim Biophys Acta. 2008;1784:56–65.
5. Koutsioumpa M, Papadimitriou E: PG receptors with phosphatase action in
cancer and angiogenesis. In Extracellular Matrix: Pathobiology and
Signalling. Edited by Karamanos N. Berlin/Boston: Walter de Gruyter GmbH
and Co KG; 2012:813–823.
6. Polykratis A, Katsoris P, Courty J, Papadimitriou E. Characterization of heparin
affin regulatory peptide signaling in human endothelial cells. J Biol Chem.
2005;280:22454–61.
7. Papadimitriou E, Mikelis C, Lampropoulou E, Koutsioumpa M, Theochari K,
Tsirmoula S, et al. Roles of pleiotrophin in tumor growth and angiogenesis.
Eur Cytokine Netw. 2009;20:180–90.
8. Mikelis C, Sfaelou E, Koutsioumpa M, Kieffer N, Papadimitriou E. Integrin
alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced
endothelial cell migration through receptor protein tyrosine phosphatase
beta/zeta. FASEB J. 2009;23:1459–69.
9. Fujikawa A, Shirasaka D, Yamamoto S, Ota H, Yahiro K, Fukada M, et al. Mice
deficient in protein tyrosine phosphatase receptor type Z are resistant to
gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet.
2003;33:375–81.
10. Nandi S, Cioce M, Yeung YG, Nieves E, Tesfa L, Lin H, et al. Receptor-type
protein-tyrosine phosphatase ζ is a functional receptor for interleukin-34.
J Biol Chem. 2013;288:21972–86.
11. Koutsioumpa M, Polytarchou C, Courty J, Zhang Y, Kieffer N, Mikelis C, et al.
Interplay between αvβ3 integrin and nucleolin regulates human endothelial
and glioma cell migration. J Biol Chem. 2013;288:343–54.
12. Koutsioumpa M, Papadimitriou E. Cell surface nucleolin as a target for anti-
cancer therapies. Recent Pat Anticancer Drug Discov. 2014;9:137–52.
13. Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y. The angiogenic function of
nucleolin is mediated by vascular endothelial growth factor and nonmuscle
myosin. Blood. 2006;107:3564–71.
14. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P,
et al. Suppression of tumor growth and angiogenesis by a specific antagonist
of the cell-surface expressed nucleolin. PLoS One. 2008;3:e2518.
15. Barel M, Le Romancer M, Frade R. Activation of the EBV/C3d receptor (CR2,
CD21) on human B lymphocyte surface triggers tyrosine phosphorylation of
the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase.
J Immunol. 2001;166:3167–73.
16. Wu DM, Zhang P, Liu RY, Sang YX, Zhou C, Xu GC, et al. Phosphorylation and
changes in the distribution of nucleolin promote tumor metastasis via the
PI3K/Akt pathway in colorectal carcinoma. FEBS Lett. 2014;588:1921–9.
17. Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, et al.
The cell-surface-expressed nucleolin is associated with the actin cytoskeleton.
Exp Cell Res. 2000;261:312–28.
18. Spiro DJ, Boll W, Kirchhausen T, Wessling-Resnick M. Wortmannin alters the
transferrin receptor endocytic pathway in vivo and in vitro. Mol Biol Cell.
1996;7:355–67.
19. Thong FS, Dugani CB, Klip A. Turning signals on and off: GLUT4 traffic in the
insulin-signaling highway. Physiology (Bethesda). 2005;20:271–84.
20. Abe M, Setoguchi Y, Tanaka T, Awano W, Takahashi K, Ueda R, et al.
Membrane protein location-dependent regulation by PI3K (III) and
rabenosyn-5 in Drosophila wing cells. PLoS One. 2009;4:e7306.
21. Lemmon MA, Ferguson KM. Signal-dependent membrane targeting by
pleckstrin homology (PH) domains. Biochem J. 2000;350(Pt 1):1–18.
22. Burks DJ, Wang J, Towery H, Ishibashi O, Lowe D, Riedel H, et al. IRS
pleckstrin homology domains bind to acidic motifs in proteins. J Biol Chem.
1998;273:31061–7.
Koutsioumpa et al. Molecular Cancer  (2015) 14:19 Page 16 of 1623. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a
humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335–45.
24. Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in
glioblastoma. CNS Oncol. 2013;2:49–65.
25. Muller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, et al. A
role for receptor tyrosine phosphatase ζ in glioma cell migration.
Oncogene. 2003;22:6661–8.
26. Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K. RNA
interference targeting protein tyrosine phosphatase ζ/receptor-type protein
tyrosine phosphatase β suppresses glioblastoma growth in vitro and in vivo.
J Neurochem. 2006;98:1497–506.
27. Pantazaka E, Papadimitriou E. Chondroitin sulfate-cell membrane effectors
as regulators of growth factor-mediated vascular and cancer cell migration.
Biochim Biophys Acta. 1840;2014:2643–50.
28. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/
phosphacan, an extracellular variant of receptor-like protein-tyrosine
phosphatase ζ/RPTPβ, binds pleiotrophin/heparin-binding growth-
associated molecule (HB-GAM). J Biol Chem. 1996;271:21446–52.
29. Maeda N, Fukazawa N, Hata T. The binding of chondroitin sulfate to
pleiotrophin/heparin-binding growth-associated molecule is regulated by
chain length and oversulfated structures. J Biol Chem. 2006;281:4894–902.
30. Tanaka M, Maeda N, Noda M, Marunouchi T. A chondroitin sulfate
proteoglycan PTPζ /RPTPβ regulates the morphogenesis of Purkinje cell
dendrites in the developing cerebellum. J Neurosci. 2003;23:2804–14.
31. Bao X, Muramatsu T, Sugahara K. Demonstration of the pleiotrophin-binding
oligosaccharide sequences isolated from chondroitin sulfate/dermatan sulfate
hybrid chains of embryonic pig brains. J Biol Chem. 2005;280:35318–28.
32. Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K. Specific molecular
interactions of oversulfated chondroitin sulfate E with various heparin-
binding growth factors. Implications as a physiological binding partner in
the brain and other tissues. J Biol Chem. 2002;277:43707–16.
33. ten Dam GB, van de Westerlo EM, Purushothaman A, Stan RV, Bulten J,
Sweep FC, et al. Antibody GD3G7 selected against embryonic
glycosaminoglycans defines chondroitin sulfate-E domains highly
up-regulated in ovarian cancer and involved in vascular endothelial
growth factor binding. Am J Pathol. 2007;171:1324–33.
34. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF)
isoforms: differential deposition into the subepithelial extracellular matrix
and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell.
1993;4:1317–26.
35. Parker MW, Xu P, Guo HF, Vander Kooi CW. Mechanism of selective VEGF-A
binding by neuropilin-1 reveals a basis for specific ligand inhibition. PLoS
One. 2012;7:e49177.
36. von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, et al.
Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon
8 of vascular endothelial growth factor. J Biol Chem. 2006;281:5702–10.
37. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, et al. Differential
induction of glioblastoma migration and growth by two forms of
pleiotrophin. J Biol Chem. 2005;280:26953–64.
38. Bermek O, Diamantopoulou Z, Polykratis A, Dos Santos C, Hamma-Kourbali
Y, Burlina F, et al. A basic peptide derived from the HARP C-terminus inhibits
anchorage-independent growth of DU145 prostate cancer cells. Exp Cell
Res. 2007;313:4041–50.
39. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault
D, et al. Heparin affin regulatory peptide binds to vascular endothelial
growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene.
2004;23:1745–53.
40. Mikelis C, Lamprou M, Koutsioumpa M, Koutsioubas AG, Spyranti Z, Zompra
AA, et al. A peptide corresponding to the C-terminal region of pleiotrophin
inhibits angiogenesis in vivo and in vitro. J Cell Biochem. 2011;112:1532–43.
41. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and
future perspectives. Cancer Lett. 2012;320:130–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
